Sanziguben polysaccharides improve diabetic nephropathy in mice by regulating gut microbiota to inhibit the TLR4/NF-κB/NLRP3 signalling pathway

Sanziguben (SZGB) is an empirical prescription used in traditional Chinese medicine to treat diabetic nephropathy (DN). As an abundant and primarily effective component of SZGB, Sanziguben polysaccharides (SZP) can be digested by flora to generate biological activity. Our study aimed to clarify the...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutical biology 2023-12, Vol.61 (1), p.427-436
Main Authors: Wang, Fan, Liu, Chang, Ren, LingZhi, Li, YanYang, Yang, HongMei, Yu, Yang, Xu, WeiPing
Format: Article
Language:English
Subjects:
Animals
Biological activity
chronic kidney diseases
Creatinine
Diabetes
Diabetes Mellitus
Diabetic Nephropathies - drug therapy
Diabetic Nephropathies - metabolism
Diabetic nephropathy
Digestive system
Enzyme-linked immunosorbent assay
Gastrointestinal Microbiome
Gastrointestinal tract
Gram-negative bacteria
Homeostasis
Inflammation
Insulin resistance
Intestinal microbiota
Intestinal microflora
Lipopolysaccharides
Male
Metformin
Mice
Microbiota
Nephropathy
NF-kappa B - metabolism
NF-κB protein
NLR Family, Pyrin Domain-Containing 3 Protein - metabolism
NLRP3 inflammasome
Oral administration
Polysaccharides
Polysaccharides - pharmacology
Polysaccharides - therapeutic use
RNA, Ribosomal, 16S
rRNA 16S
Signal transduction
TLR4 protein
Toll-Like Receptor 4 - metabolism
Toll-like receptors
Traditional Chinese medicine
Western blotting
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sanziguben (SZGB) is an empirical prescription used in traditional Chinese medicine to treat diabetic nephropathy (DN). As an abundant and primarily effective component of SZGB, Sanziguben polysaccharides (SZP) can be digested by flora to generate biological activity. Our study aimed to clarify the potential mechanism of SZP in improving chronic DN. Male db/db mice were randomized into DN, SZP (500 mg/kg) and metformin (MET, 300 mg/kg) groups. Wild-type littermates served as the normal control (NC) group. The drug was orally administered for 8 weeks. Enzyme-linked immunosorbent assay was used to detect the inflammatory factors. Proteins related to inflammation were evaluated using western blotting and immunohistochemical examination. Gut microbiota was analysed using 16S rRNA sequencing. SZP significantly reduced 24 h urine albumin (p 
ISSN:1388-0209
1744-5116
DOI:10.1080/13880209.2023.2174145